Several studies have shown that inhibition of Sct-dependent signaling in BDL and Mdr2−/− mice (by genetic knockout or pharmacological inhibition of SR) reduces biliary damage/DR and liver fibrosis by inhibiting TGFβ1 signaling [9, 17]. This evidence concerns the gene TGFB1 and Hepatic fibrosis.